DIAN-TU Data and Biospecimen Sharing, Publication, Authorship and Citation Policies
Qualified researchers get de-identified trial data for research approved by DIAN-TU, with Industry Collaborators able to review requests and manuscripts. Requires IRB or ethics documentation and a Data Use Agreement; no sharing with third parties; data destroyed after analysis; every publication or presentation is reviewed and approved by DIAN-TU first.
Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer
What you can do
- Not stated
- Not stated
- Conditional
- Conditional
What you can share
- No
- Not stated
- Share trained models Not stated
What you must do
- Yes
- Share alike No
- Yes
- Yes
- Yes
- Conditional
- Conditional
- Yes
Limits
- Yes
- No
Datasets under this license
- DIAN-TU-001 (gantenerumab and solanezumab arms)
Phase II/III placebo-controlled trial of gantenerumab or solanezumab in 142 carriers of dominantly inherited Alzheimer disease mutations, with frequent 3T safety MRI (FLAIR, 2D T2*-GRE) centrally read for ARIA-E and ARIA-H, PiB PET, CSF and cognition.